Observational study for detailed blood sugar (BS) fluctuation in myotoic dystrophy by continuous glucose monitoring (CGM)

Observational study for detailed blood sugar (BS) fluctuation in myotoic dystrophy by continuous glucose monitoring (CGM) - BS fluctuation in myotonic dystrophy: CGM observational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000017800

Enrollment

Registered

2015-06-15

Start date

2015-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myotonic dystrophy type 1 Amyotrophic neuromuscular disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Genetically diagnosed case in myotonic dystrophy 2.Fasting BS < 130mg/dl and HbA1c < 7.0% 3.Without limitation for stage or severity of disease

Exclusion criteria

Exclusion criteria: 1.Medicated by insulin, DPP-4 inhibitor or GLP-1 agonist 2.Serious infection, perioperative or serious injury 3.Cardio-vascular event 4.Serious liver damage 5.Moderate or serious renal damage 6.Moderate or serious heart failure 7.Gestation or lactation period 8.Short bowel syndrome 9.Medicated by steroid, interferon, hormonal agent, atypical antipsychotic 10.Emaciation or skin disease with difficulty to be attached CGM 11.No informed consent with a form 12.Assessed as inadequate by a physician in charge

Design outcomes

Primary

Measure	Time frame
Index by CGM (mean BS, SD of BS, M value, MAGE, BS area, proportion of hypoglycemia or hyperglycemia) and routine blood examination	—

Secondary

Measure	Time frame
Results of oral glucose tolerance test	—

Countries

Japan

Contacts

Public ContactHiroto TAKADA

National Aomori Hospital Neurology

takada@aomorihosp.jp+81-172-62-4055

Outcome results